Anti-Human 4-1BB Recombinant Antibody (TAB-179)

Customer Review

There are currently no Customer reviews or questions for TAB-179. Click the button above to contact us or submit your feedback about this product.

Michael Johnson
21.Sep,23

Excellent for Immune Research

The Anti-Human 4-1BB Therapeutic Antibody (Urelumab) has significantly improved our immune cell studies. The specificity and sensitivity are outstanding, providing clear and reproducible results. This antibody has become essential for our research, enhancing the accuracy and reliability of our assays.

Laura Brown
14.Nov,22

Effective in Flow Cytometry

We incorporated this antibody into our flow cytometry experiments, and it's been a great asset. The specificity for 4-1BB is precise, allowing for accurate cell population analysis. The reliable performance has made it an invaluable tool in our lab.

John Wilson
19.Jun,21

Consistent and Reliable

This antibody has proven to be consistent and reliable in our immunoassays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for 4-1BB have been particularly beneficial.

Q&As

1. Is the anti-Human 4-1BB therapeutic antibody Urelumab suitable for use in ELISA?

   A: Yes, the anti-Human 4-1BB therapeutic antibody Urelumab (TAB-179) is suitable for use in ELISA. It has been validated for use in such assays and provides reliable detection of 4-1BB.

2. What is the optimal dilution for using the anti-Human 4-1BB therapeutic antibody Urelumab in Western blotting?

   A: The optimal dilution for using the anti-Human 4-1BB therapeutic antibody Urelumab (TAB-179) in Western blotting is typically 1:500 to 1:2000. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

3. Can the anti-Human 4-1BB therapeutic antibody Urelumab be used in flow cytometry analysis?

   A: Yes, the anti-Human 4-1BB therapeutic antibody Urelumab (TAB-179) can be used in flow cytometry analysis. It is specifically designed to bind to 4-1BB, making it suitable for detecting 4-1BB-expressing cells in flow cytometry.

4. Is the anti-Human 4-1BB therapeutic antibody Urelumab effective in blocking 4-1BB interactions in vitro?

   A: Yes, the anti-Human 4-1BB therapeutic antibody Urelumab (TAB-179) is effective in blocking 4-1BB interactions in vitro. It can inhibit the interaction between 4-1BB and its ligands, which is useful for studying the immune signaling pathways involving 4-1BB.

5. What are the storage recommendations for the anti-Human 4-1BB therapeutic antibody Urelumab?

   A: The recommended storage condition for the anti-Human 4-1BB therapeutic antibody Urelumab (TAB-179) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Reithofer, Manuel, et al. "4-1BB costimulation promotes bystander activation of human CD8 T cells." European Journal of Immunology 51.3 (2021): 721-733. https://doi.org/10.1002/eji.202048762
   This study explores the impact of 4-1BB costimulation on human CD8 T cells, particularly focusing on bystander activation. The researchers used engineered antigen-presenting cells (eAPCs) expressing viral epitopes and costimulatory ligands to study how different costimulatory signals affect CD8 T cell responses. They found that while CD28 costimulation enhances antigen-specific CD8 T cell responses, 4-1BB costimulation, either through 4-1BB ligand (4-1BBL) or the agonist antibody urelumab, induces significant bystander proliferation of CD8 T cells and expansion of NK cells. This bystander activation is independent of the presented antigens and is characterized by increased cytokine production and cytotoxic activity.
   Creative Biolabs contributed significantly to this research by providing the 4-1BB agonist antibody urelumab (Cat# TAB-179). This antibody was crucial for experiments investigating the effects of 4-1BB costimulation on CD8 T cells and NK cells. The use of urelumab enabled the researchers to demonstrate the unique ability of 4-1BB signals to promote bystander activation, thereby advancing the understanding of how 4-1BB costimulation can be harnessed in cancer immunotherapy while also highlighting potential off-target effects that need to be managed.
2. Upadhyaya, Punit, et al. "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist." Journal for immunotherapy of cancer 9.1 (2021). https://doi.org/10.1136/jitc-2020-001762
   This study investigates the development and efficacy of synthetic tumor-targeted CD137 agonists (TICAs) in inducing anticancer immunity. By using constrained bicyclic peptides (Bicycles) to create TICAs that link tumor antigens (like EphA2) with costimulatory receptors (such as CD137), the researchers were able to selectively activate these receptors in the presence of tumor cells. The study demonstrated that the EphA2/CD137 TICA (BCY12491) efficiently stimulated human peripheral blood mononuclear cells and resulted in significant tumor regression in mouse models. This approach highlights the potential of TICAs to provide effective and targeted cancer immunotherapy with a wide therapeutic index.
   Creative Biolabs contributed to this research by supplying the anti-CD137 monoclonal antibody urelumab (Cat# TAB-179). This antibody was crucial for the experiments that investigated the effects of 4-1BB (CD137) costimulation on immune cells. The provision of this key reagent allowed researchers to demonstrate the unique capabilities of TICAs in promoting targeted tumor immunity, thereby supporting the development of new therapeutic strategies in cancer treatment.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-179, RRID: AB_3111852)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Urelumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Urelumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "TNFRSF9"

Select a product category from the dropdown menu below to view related products.